Probiotics in Infants With Gastroschisis

NCT ID: NCT01316510

Last Updated: 2018-07-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants born with gastroschisis usually require surgery shortly after birth. After surgery the intestine is often unable to digest human milk or formula for weeks or months. During this time the baby has to remain in the hospital to receive special nutrition through an IV. How bacteria colonize the intestine in these babies is unknown. Probiotics are bacteria that appear to have beneficial effects on digestion. This study will test whether giving probiotic bacteria to babies after surgery for gastroschisis will change the bacteria in the intestine to be more like those of a healthy breast-fed baby.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infants with gastroschisis have decreased intestinal motility. This decrease in intestinal motility delays the introduction and advancement of feeds which prolongs hospitalization. The use of probiotic bacteria may improve intestinal motility. It is unknown whether the intestinal microbiota of infants with gastroschisis differs from that of healthy infants without gastroschisis and whether probiotics will change the microbiota. The primary outcome in this study is the composition of the fecal microbiota in infants with gastroschisis following surgical correction treated with Bifidobacterium infantis or placebo. We will also look at differences in hospital length of stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroschisis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bifidobacteria infantis

1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)

Group Type ACTIVE_COMPARATOR

Bifidobacteria infantis

Intervention Type DIETARY_SUPPLEMENT

1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge

Placebo

A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Dilute Nutramigen formula

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bifidobacteria infantis

1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge

Intervention Type DIETARY_SUPPLEMENT

Placebo

Dilute Nutramigen formula

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gastroschisis
* Born at or transferred to UC Davis Children's hospital

Exclusion Criteria

* None
Maximum Eligible Age

2 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark A Underwood, MD

Role: PRINCIPAL_INVESTIGATOR

UC Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UC Davis Children's Hospital

Sacramento, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Powell WT, Borghese RA, Kalanetra KM, Mirmiran M, Mills DA, Underwood MA. Probiotic Administration in Infants With Gastroschisis: A Pilot Randomized Placebo-Controlled Trial. J Pediatr Gastroenterol Nutr. 2016 Jun;62(6):852-857. doi: 10.1097/MPG.0000000000001031.

Reference Type DERIVED
PMID: 26545203 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201018539

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infant Microbiota and Probiotic Intake Study
NCT02457338 ACTIVE_NOT_RECRUITING NA
Cesarean Section Study
NCT01992497 COMPLETED NA
Probiotics in Short Bowel Syndrome
NCT03980327 COMPLETED NA
Probiotic for Infants
NCT07054216 RECRUITING NA
Probiotics for Preterm Infants
NCT06885944 NOT_YET_RECRUITING